zurück

Mosunetuzumab (follicular lymphoma (FL), ≥ 2 prior therapies)

 

Subject:

  • Active Substance: Mosunetuzumab
  • Name: Lunsumio®
  • Therapeutic area: Follicular lymphoma (FL)
  • Pharmaceutical company: Roche Pharma AG

 

Time table:

  • Start: 01.07.2022
  • Final decision by G-BA: 15.12.2022

 

Final decision:

  • Hint for a non-quantifiable additional benefit